FIELD T-2 

 Columns 58, 59, 60, and 61 



1621 Hastening of death due to the pathology 172 



(in Field E) which is lethal to untreated 

 controls; decrease in survival time. 

 Acceleration of the progress of a fatal 

 disease is ordinarily evaluated in 

 Field Y by Criterion 12 or 57, coding 

 the decrease in survival time in Field U. 



163 Intensification of the disease by 



specifically increasing the disease 

 beyond its normal peak intensity ; i. e. , 

 intensification by influencing the dis- 

 ease to a greater intensity than that to 

 which it would normally progress. 

 1631 Decrease of the number of survivors of 



the pathology (in Field E) which causes 1721 



a known mean mortality rate when 



untreated; increase in the number of 



deaths due to such a pathology which is 



lethal to untreated controls. With 



Symbol 1631, evaluation in Field Y is 



based on the percentage decrease of 



survivors and the expression, decrease 173 



of the number of survivors, should be 



in the written portion of Field T-2. 



164 Increase in duration of the pathology; 



prolongation of the symptoms beyond 

 the normal duration. 



17 Relief (general or unspecified) from the 



pathology condition in Field E. (See 

 the note prior to Symbol 16. ) Use 

 other symbols of this 17-- series for 

 specific degrees of alleviation of the 

 pathology and for preventive actions. 174 



171 Decrease in number of individuals of the 



pathogenic organism species coded in 

 Field E. This symbol is used for effects 

 on infectious diseases only. Evaluation 

 in Field Y is to be based on the decrease 

 of the number of pathogens. Criterion 62 

 or 01 (or 03 or 04). Use Symbol 171 if 

 the reduction of pathogens is incomplete; 

 when the reduction is complete, use Sym- 

 bol 1711; when reduction is due to an 

 increase in the resistance of the host to 175 



the pathogen, use Symbol 1712. 



1711 Biological cure (infectious diseases). 



Demonstrated, 100% decrease in the 

 number of individuals of the pathogenic 

 organism species coded in Field E; ster- 

 ilization of the host coded in Field J. 1751 

 Evaluation in Field Y is to be based on 

 the potency of the test compound for 

 bringing about cure, not on the percent- 

 age of decrease in individuals of the 

 infecting pathogen. 



1712 Decrease in the number of individuals of 



the pathogenic organism species due to 

 the test compound's causing an increase 

 in the resistance of the host to the 

 pathogenic organism. 



Clinical cure (non-infectious diseases 

 as well as infectious); permanent 

 eradication of symptoms. (In the case 

 of clinical cure of infectious diseases , 

 use Symbol 172, if sterilization is not 

 demonstrated but symptoms do not 

 reappear. Use Symbol 1711, if sterili- 

 zation is demonstrated. Use Symbol 

 1721, if the pathogen is demonstrated 

 to persist in spite of clinical cure. 

 Use Symbol 173, if the pathogen is 

 demonstrated to persist after disap- 

 pearance of symptoms and subsequently 

 causes symptoms again. ) 



Carrier state (infectious diseases). Use 

 Symbol 1721 for clinical cures caused 

 by the test compound in which the 

 pathogenic organism remains demon- 

 strable in the host but the symptoms 

 prove to have been permanently 

 eradicated. 



Temporary cure. ( Non-infectious dis - 

 eases : use Symbol 172, if the disease 

 is demonstrated to be permanently 

 clinically cured. Infectious diseases : 

 use Symbol 1721, if the pathogen 

 remains with its host but produces no 

 symptoms thereafter, due to the test 

 compound's effect; however, use Symbol 

 173, if the pathogen remains with its 

 host but produces symptoms subsequent 

 to a clinical cure. ) 



Prevention of the infectious or non- 

 infectious pathology. If the test 

 compound acts only after the disease 

 has been contracted, use Symbol 176 

 or other symbols. If application results 

 in the test compound's being a physical 

 barrier on the skin or mucous membrane 

 preventing penetration by pathogenic 

 organisms, or preventing damage due 

 to physical agents such as radiation, 

 use Symbol 178. 



Repression of either an infectious or 

 non-infectious existing pathology 

 treated by the test compound. Use 

 Symbols 1751 or 17 52, if the nature of 

 repression is demonstrated and fits the 

 description of one of those symbols. 



Retardation of progress of the infectious 

 or non-infectious existing pathology. 

 (Slowing of the development of the 

 disease which nevertheless progresses 

 to its normal peak. ) 

 Note: Use Symbol 17 51 only for 

 retardation of diseases which are in 

 themselves ordinarily not fatal; if 

 death is the ultimate result of the 

 disease in untreated controls, the re- 

 tarding effect should be coded as an 



- 146 



